https://www.selleckchem.com/pr....oducts/pf-06650833.h
70, 95% CI 1.56-4.66; seven studies; I2 = 57%) and opportunistic infections (3.16, 1.09-9.20; four studies; I2 = 73%). The occurrence of any infection (1.67, 0.51-5.43; five studies; I2 = 75%) and cancer (0.90, 0.64-1.26; nine studies; I2 = 0%) was not significantly affected. Nevertheless, our confidence in the effect estimates is rather limited; the quality of evidence is low to very low. CONCLUSIONS Biologics are likely to increase the risk of serious and opportunistic infections in old IBD patients. Large prospective studies are